13.11.20: Not intended for U.S. and UK Media

Positive CHMP opinion for extension of rivaroxaban marketing authorization to treat venous thromboembolism (VTE) in childrenPediatric patients currently have limited therapeutic options and until now, there have been no approved oral treatments because of the absence of appropriate clinical trials / After approval, rivaroxaban would be the only oral Factor Xa Inhibitor authorized to treat VTE and prevent VTE recurrence in children / An oral suspension of rivaroxaban that does not require injections or regular monitoring has been developed to facilitate pediatric administration / CHMP opinion is based on the largest pediatric thromboembolism program completed to date, including the phase III EINSTEIN-Jr. studymehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news